global target, page-11

I put some significant money into the rights issue recently and there is no way in the world I put more into it if I could see they would need to do another cap raising this year. In fact I don't think they will need to do another cap raising at all because once FDA approval is given the profits will be significant to carrying on business and expand it as should be.

The price action speaks that this is still undervalued according to its potential NEAR TERM sales potential.

If anyone wants to know the potential markets DYOR by starting to read, then re read the 13/6/07 presentation, then read every other announcement since then.